Immune Therapeutics, Inc.

IMUN · OTC
Analyze with AI
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenue$0$0$0$0
% Growth
Cost of Goods Sold$0$0$0$0
Gross Profit$0$0$0$0
% Margin
R&D Expenses$0$0$0$0
G&A Expenses$0$1$1$3
SG&A Expenses$1$1$1$3
Sales & Mktg Exp.$0$0$0$0
Other Operating Expenses$0$0$0$0
Operating Expenses$1$1$1$3
Operating Income-$1-$1-$1-$3
% Margin
Other Income/Exp. Net-$2$4$2-$1
Pre-Tax Income-$4$4$2-$3
Tax Expense$2$0$0$1
Net Income-$6$4$1-$5
% Margin
EPS-0.167.412.4-10.44
% Growth-102.2%208.8%123%
EPS Diluted-0.160.382.4-10.44
Weighted Avg Shares Out36000
Weighted Avg Shares Out Dil36900
Supplemental Information
Interest Income$0$0$0$0
Interest Expense$0$0$0$1
Depreciation & Amortization$1$3-$0$0
EBITDA-$1$2-$1-$2
% Margin
Immune Therapeutics, Inc. (IMUN) Financial Statements & Key Stats | AlphaPilot